Frank D’Amelio to Step Down as Pfizer CFO

Frank D’Amelio is retiring as CFO of Pfizer right after a fourteen-12 months tenure during which he performed important roles in transformative transactions and the drugmaker’s response to the COVID-19 pandemic.

Pfizer reported Wednesday it had begun an external lookup for D’Amelio’s successor and that he had agreed to keep with the organization by means of the process and provide in a consulting function by means of the changeover.

Frank D’Amelio

In addition to his finance main function, D’Amelio has served as government vice president for worldwide offer given that he joined Pfizer in 2007.

“I want to thank Frank for his quite a few many years of company to Pfizer as CFO and for the effect he has had on the organization and the clients we provide,” CEO Albert Bourla reported in a news release.

“Frank has pushed a strategic eyesight for the company’s economic success, and he leaves Pfizer in a solid position for upcoming progress having been instrumental in our multi-12 months transformation to an market-primary, science-based mostly biopharmaceutical organization,” he reported.

As section of that transformation, D’Amelio oversaw the divestitures of Pfizer’s animal overall health, shopper overall health, and experienced solutions organizations and the $68 billion acquisition of Wyeth in 2009. For the duration of his tenure as CFO, Pfizer generated close to $150 billion in sector cap progress.

Most just lately, Pfizer reported, he “helped manual the organization by means of 1 of its most tough intervals as it worked to handle the COVID-19 disaster.”

D’Amelio’s successor will be accountable for deploying the dollars that Pfizer is generating from its COVID-19 vaccines. The organization is also searching for Fda unexpected emergency approval for a capsule to take care of the virus.

Probable employs of the vaccine dollars contain acquisitions, partnerships, or share repurchases, in accordance to Damien Conover, an analyst at Morningstar. “It’s going to be a big windfall,” he instructed The Wall Avenue Journal. “They’re going to have to execute genuinely properly on redeploying that capital.”

Right before signing up for Pfizer, D’Amelio acquired almost three a long time of extensive running and economic working experience at AT&T, Lucent Technologies, and Alcatel-Lucent. He begun his occupation in 1979 at Bell Labs.

Albert Bourla, COVID-19, Frank D’Amelio, Pfizer, retirement